NCT05440838View on ClinicalTrials.gov

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.

Not yet recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

September 7, 2024

Study Completion Date

October 4, 2029

Conditions
Myeloproliferative Neoplasm
Interventions
DIAGNOSTIC_TEST

Next-generation sequencing

Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.

All Listed Sponsors
collaborator

University Hospital, Brest

OTHER

collaborator

Nantes University Hospital

OTHER

collaborator

Poitiers University Hospital

OTHER

collaborator

Rennes University Hospital

OTHER

collaborator

University Hospital, Tours

OTHER

lead

University Hospital, Angers

OTHER_GOV

NCT05440838 - Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. | Biotech Hunter | Biotech Hunter